Comparison of 177Lu-DOTA-ZOL to Other Radiopharmaceuticals Used for Bone Metastasis Treatment
| Parameter | 177Lu-DOTA-ZOL | 89SrCl2 (33) | 153Sm-EDTMP (34) | 177Lu-EDTMP (34) | 188Re-HEDP (35) | 223Ra-Cl2* |
|---|---|---|---|---|---|---|
| Tumor lesion | 4.21 ± 2.40 | 233 ± 166 | 6.22 ± 4.21 | 6.92 ± 3.92 | 3.83 ± 2.01 | 179.8 (68–490) (36) |
| Red marrow | 0.36 ± 0.12 | 18.9 | 1.41 ± 0.6 | 0.83 ± 0.21 | 0.61 ± 0.21 | 73.9 (37) |
| Bone surface | 1.19 | 30.2 | 7.8 | NA | 1.403 | 739.1 (37) |
| Tumor–to–red-marrow dose ratio | 13.9 | 12.3 | 4.40 | 8.31 | 6.28 | 2.4 |
| Tumor–to–bone-surface dose ratio | 3.5 | 7.7 | 0.8 | NA | 2.7 | 0.2 |
↵* 223Ra is α-emitter; therefore, relative biological effectiveness factor of 5 needs to be applied for comparison with β−-emitters (relative biological effectiveness = 1).
NA = not applicable.
Values are normalized absorbed doses (Gy/GBq) as mean ± SD. Tumor–to–red-marrow dose ratio and tumor–to–bone-surface dose ratio were calculated as mean of dose ratios for each patient. Bone surface dose was estimated using bone-to-red marrow dose ratios of 1.6 for 89SrCl2 (38), 5.5 for 153Sm-EDTMP (38), and 2.3 for 186Re-HEDP (38). Dose-limiting organ was red marrow.